These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18837828)

  • 1. The need for an evidence-based decision-making process with regard to control of hepatitis A.
    Gentile A
    J Viral Hepat; 2008 Oct; 15 Suppl 2():16-21. PubMed ID: 18837828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China.
    Zhuang GH; Pan XJ; Wang XL
    Vaccine; 2008 Aug; 26(35):4608-16. PubMed ID: 18597903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility of universal hepatitis A vaccination in Canada.
    Bauch CT; Anonychuk AM; Pham BZ; Gilca V; Duval B; Krahn MD
    Vaccine; 2007 Dec; 25(51):8536-48. PubMed ID: 17996339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context.
    Sartori AM; de Soárez PC; Novaes HM; Amaku M; de Azevedo RS; Moreira RC; Pereira LM; Ximenes RA; Martelli CM
    Vaccine; 2012 Dec; 30(52):7489-97. PubMed ID: 23107593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program.
    Chodick G; Heymann AD; Ashkenazi S; Kokia E; Shalev V
    J Viral Hepat; 2008 Oct; 15 Suppl 2():62-5. PubMed ID: 18837837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis A vaccine recommendations.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jul; 120(1):189-99. PubMed ID: 17606579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations.
    Ceyhan M; Yildirim I; Kurt N; Uysal G; Dikici B; Ecevit C; Aydogan A; Koc A; Yasa O; Köseoğlu M; Onal K; Hacimustafaoglu M; Celebi S
    J Viral Hepat; 2008 Oct; 15 Suppl 2():69-72. PubMed ID: 18837839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal hepatitis A vaccination in the United States: a call for action.
    Lieberman JM; Word BM; Jacobs RJ; Dagan R; Marchant CD
    Pediatr Infect Dis J; 2008 Apr; 27(4):287-91. PubMed ID: 18316993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.
    Deneke MG; Arguedas MR
    Expert Rev Vaccines; 2003 Oct; 2(5):661-72. PubMed ID: 14711327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of the single-dose immunization strategy against hepatitis A in Argentina.
    Vizzotti C; Pippo T; Urueña A; Altuna J; Palópoli G; Hernández ML; Artola MF; Fernández H; Orellano P; Cañero-Velasco MC; Ciocca M; Ramonet M; Diosque M
    Vaccine; 2015 May; 33 Suppl 1():A227-32. PubMed ID: 25919166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of early hepatitis B immunization programs for newborns and infants.
    Van Herck K; Van Damme P
    Pediatr Infect Dis J; 2008 Oct; 27(10):861-9. PubMed ID: 18776823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.
    Chapko MK; Yee HS; Monto A; Dominitz JA
    Vaccine; 2010 Feb; 28(7):1726-31. PubMed ID: 20044051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis.
    Duncan M; Hirota WK; Tsuchida A
    Am J Gastroenterol; 2002 Jul; 97(7):1792-5. PubMed ID: 12135037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shifting epidemiology of hepatitis A following routine childhood immunization program in Israel.
    Chodick G; Green MS; Heymann AD; Rosenmann L; Shalev V
    Prev Med; 2007 Nov; 45(5):386-91. PubMed ID: 17599401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Hepatitis A in Argentina after vaccination.
    Vacchino MN
    J Viral Hepat; 2008 Oct; 15 Suppl 2():47-50. PubMed ID: 18837834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.